Clinical takeaway: The CAROLINA trial
John Wilding outlines the key take-home message from the CAROLINA trial comparing the cardiovascular risk profile of the dipeptidyl peptidase-4 inhibitor linagliptin and the sulfonylurea glimepiride (0:37).
- News story | CAROLINA shows neutral cardiovascular profile for modern sulfonylurea
- Expert commentary | An endocrinologist's view of the CAROLINA trial
- News story | Real-world hypoglycemia data support continued sulfonylurea role in type 2 diabetes
- News story | TOSCA.IT: Similar long-term CV safety profile for pioglitazone, sulfonylurea